Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017.
Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.
In 4Q15, Bioventus commenced U.S. distribution of the product to treat knee OA pain via repeat injection cycles. Also in the U.S., through an agreement announced in 1Q16, Bioventus will distribute GELSYN-3™ 3-injection hyaluronic acid for knee OA pain relief starting in 3Q16.
Bioventus has just registered for a US $150MM initial public offering.
Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017.
Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.
In 4Q15,...
Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017.
Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.
In 4Q15, Bioventus commenced U.S. distribution of the product to treat knee OA pain via repeat injection cycles. Also in the U.S., through an agreement announced in 1Q16, Bioventus will distribute GELSYN-3™ 3-injection hyaluronic acid for knee OA pain relief starting in 3Q16.
Bioventus has just registered for a US $150MM initial public offering.
Copy to clipboard 
